ABSTRACT
Background The treatment of ovarian carcinomatosis with cytoreductive surgery and HIPEC is still controversial. The effect and pharmacokinetics of the chemotherapeutics used (specially taxanes) are under consideration at present.
Methods A phase II, simple blind and randomized controlled trial (NTC02739698) was performed. Thirty-two patients with primary or recurrent ovarian carcinomatosis undergoing cytoreductive surgery (CRS) and intraoperative intraperitoneal chemotherapy with paclitaxel (PTX) were included; 16 in hyperthermic and 16 in normothermic conditions. Tissue, serum and plasma samples were taken in every patient before and after intraperitoneal chemotherapy to measure the concentration of PTX. To analyze the inmunohistochemical profile of p53, p27, p21, ki67, PCNA, caspasa-3 and the pathological response a scale of intensity and percentage of expression and a grouped Miller and Payne system were used, respectively. Perioperative characteristics and morbi-mortality were also analyzed.
Results Main characteristics of patients, surgical morbidity, haematoxicity and nephrotoxicity were similar in both groups. The concentration of paclitaxel in the tissue was higher than that observed in plasma and serum, although no statistically significant differences were found between the two groups. No statistically significant association regarding pathological response and apoptosis (caspasa-3) between both groups was proved. Intraperitoneal PTX reduced the expression of p53, p27, p21, ki67 and PCNA more in hyperthermia group, but not significantly.
Conclusion The use of intraperitoneal PTX has proven an adequate pharmacokinetics with reduction of cell cycle and proliferation markers globally without finding differences between its administration in hyperthermia versus normothermia conditions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02739698
Funding Statement
This research was supported by Aid Biomedical Research and Health Sciences in Andalucia and by The Public Foundation Progress and Health Andalusian, Health Counseling, Junta de Andalucia. PI 0678-10.EudraCT number: 2011-004373-89.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research project has been approved by the biomedical research ethics committee of the Reina Sofia Hospital in Cordoba
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST: There are no conflicts of interest in the work submitted or participating authors.
This research was supported by “Aid Biomedical Research and Health Sciences in Andalucia” and by The Public Foundation Progress and Health Andalusian, Health Counseling, Junta de Andalucia. PI 0678-10. Nº EudraCT: 2011-004373-89.
ClinicalTrial.gov Identifier: NCT02739698.
Mail address: lidiaortiz1{at}gmail.com
Mail address: sebastian.rufian.sspa{at}juntadeandalucia.es
Mail address: fcocris{at}telefonica.net
Mail address: caromariateresa{at}yahoo.es
Mail address: rosam.ortega.sspa{at}juntadeandalucia.es
Mail address: q32fepem{at}uco.es
Mail address: qa1lucam{at}uco.es
Mail address: juanmanuelsanchezhidalgo{at}hotmail.com
Mail address: chervas{at}uco.es
Mail address: antonioromeroruiz{at}gmail.com
Mail address: javibriceno{at}hotmail.com
Mail address: alvaroarjona{at}hotmail.com
Data Availability
All data produced in the present work are contained in the manuscript
